These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32105590)

  • 1. Efficacy and safety of ixekizumab in psoriatic arthritis: a retrospective, single-centre, observational study in a real-life clinical setting.
    Manfreda V; Chimenti MS; Canofari C; Esposito M; Perricone R; Bianchi L; Giunta A
    Clin Exp Rheumatol; 2020; 38(3):581-582. PubMed ID: 32105590
    [No Abstract]   [Full Text] [Related]  

  • 2. Ixekizumab in the treatment of psoriatic arthritis.
    Lespessailles E; Toumi H
    Immunotherapy; 2021 Jan; 13(1):19-33. PubMed ID: 33167745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
    Vu TT; Gooderham M; Papp K
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ixekizumab for the treatment of psoriasis: an update on new data since first approval.
    Blegvad C; Skov L; Zachariae C
    Expert Rev Clin Immunol; 2019 Feb; 15(2):111-121. PubMed ID: 30589394
    [No Abstract]   [Full Text] [Related]  

  • 5. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
    Nash P; Kirkham B; Okada M; Rahman P; Combe B; Burmester GR; Adams DH; Kerr L; Lee C; Shuler CL; Genovese M;
    Lancet; 2017 Jun; 389(10086):2317-2327. PubMed ID: 28551073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
    Mease PJ; van der Heijde D; Ritchlin CT; Okada M; Cuchacovich RS; Shuler CL; Lin CY; Braun DK; Lee CH; Gladman DD;
    Ann Rheum Dis; 2017 Jan; 76(1):79-87. PubMed ID: 27553214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis.
    Gottlieb AB; Papp KA; Birbara CA; Shuler CL; Burge R; Erickson J; Kerr L; Mease PJ
    J Am Acad Dermatol; 2018 Sep; 79(3):593-595. PubMed ID: 29559395
    [No Abstract]   [Full Text] [Related]  

  • 8. Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis.
    Toussirot E
    Expert Opin Biol Ther; 2018 Jan; 18(1):101-107. PubMed ID: 29187009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis.
    Gladman DD; Orbai AM; Klitz U; Wei JC; Gallo G; Birt J; Rathmann S; Shrom D; Marzo-Ortega H
    Arthritis Res Ther; 2019 Jan; 21(1):38. PubMed ID: 30696483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
    Mease PJ; Smolen JS; Behrens F; Nash P; Liu Leage S; Li L; Tahir H; Gooderham M; Krishnan E; Liu-Seifert H; Emery P; Pillai SG; Helliwell PS;
    Ann Rheum Dis; 2020 Jan; 79(1):123-131. PubMed ID: 31563894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials.
    Mease P; Roussou E; Burmester GR; Goupille P; Gottlieb A; Moriarty SR; Benichou O; Adams DH; Xu W; Nash P
    Arthritis Care Res (Hoboken); 2019 Mar; 71(3):367-378. PubMed ID: 30156760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of circulating invariant T cells before and after IL-17 inhibitor treatment in a patient with psoriatic arthritis.
    Koga T; Matoba M; Sato T; Koike Y; Endo Y; Sumiyoshi R; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kawakami A
    Clin Immunol; 2018 Dec; 197():107-109. PubMed ID: 30248399
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).
    van der Heijde D; Gladman DD; Kishimoto M; Okada M; Rathmann SS; Moriarty SR; Shuler CL; Carlier H; Benichou O; Mease PJ
    J Rheumatol; 2018 Mar; 45(3):367-377. PubMed ID: 29247148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term tocilizumab efficacy in a patient with psoriatic arthritis and AA amyloidosis.
    Dinoia L; Lopalco G; Cantarini L; Gesualdo L; Rossini M; Iannone F
    Clin Exp Rheumatol; 2017; 35(1):170-171. PubMed ID: 27908297
    [No Abstract]   [Full Text] [Related]  

  • 16. Ustekinumab for the treatment of psoriatic arthritis.
    Chandler DJ; Bewley A
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):111-21. PubMed ID: 24494794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful use of tocilizumab in a patient with psoriatic arthritis.
    Hughes M; Chinoy H
    Rheumatology (Oxford); 2013 Sep; 52(9):1728-9. PubMed ID: 23424264
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2.
    Genovese MC; Combe B; Kremer JM; Tsai TF; Behrens F; Adams DH; Lee C; Kerr L; Nash P
    Rheumatology (Oxford); 2018 Nov; 57(11):2001-2011. PubMed ID: 30053162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).
    Gottlieb AB; Strand V; Kishimoto M; Mease P; Thaçi D; Birt J; Lee CH; Shuler CL; Lin CY; Gladman DD
    Rheumatology (Oxford); 2018 Oct; 57(10):1777-1788. PubMed ID: 29945203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals.
    Pham PA; Dressler C; Eisert L; Nast A; Werner RN
    Rheumatol Int; 2019 Apr; 39(4):605-618. PubMed ID: 30684041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.